Medicine Access Programmes: what do patients think – a patient‐reported outcome study on ribociclib in metastatic breast cancer in Australia

This study evaluated patient‐reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expre...

Full description

Saved in:
Bibliographic Details
Published in:Internal medicine journal 2024-11, Vol.54 (11), p.1894-1897
Main Authors: Yap, Natasha, Wong, Vanessa, Morton, Catherine, Boer, Richard, Baron‐Hay, Sally, Blum, Robert, Forster, Benjamin, Chua, Susan, Clarke, Kerrie, Cuff, Katharine, Green, Michael, Lim, Elgene, Mok, Kelly, Nott, Louise, Nottage, Michelle, Tafreshi, Ali, Tsoi, Daphne, Uccellini, Anthony, Gibbs, Peter, Lok, Sheau Wen
Format: Article
Language:English
Subjects:
Adult
Aged
Aminopyridines - therapeutic use
Antineoplastic Agents - therapeutic use
Australia
Breast cancer
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Female
Health Services Accessibility
Humans
Medication Access Programme
Medication Adherence
Metastases
Middle Aged
Neoplasm Metastasis
Patient Reported Outcome Measures
patient‐reported outcome
Purines - therapeutic use
quality of life
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study evaluated patient‐reported outcomes (PROs) of Medicine Access Programmes (MAPs) for Australian metastatic breast cancer patients on ribociclib. Limited patient awareness of MAP enrolment was identified, emphasising the need for improved education and consent processes. Most patients expressed gratitude for accessing non‐funded medications and perceived enhanced medication adherence as a key benefit. Integrating PRO data with real‐world registry data provides comprehensive insight for future MAP development.
ISSN:1444-0903
1445-5994
1445-5994
DOI:10.1111/imj.16536